Claims for Patent: 9,763,932

Summary for Patent: 9,763,932

Title:	Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US15/236,290
Patent Claims:	1. A method of enhancing the bioavailability of dextromethorphan comprising co-administering to a human being twice a day for at least 14 consecutive days a combination of: a. a bupropion, a hydroxybupropion, a threohydroxybupropion, or an erythrohydroxybupropion; with b. a dextromethorphan; wherein co-administration of the bupropion, the hydroxybupropion, the threohydroxybupropion, or the erythrohydroxybupropion, with the dextromethorphan results in an onset of action for the dextromethorphan within two weeks from the first administration of the combination; wherein the human being is an extensive metabolizer of the dextromethorphan in need of treatment with dextromethorphan; wherein the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion is administered in an amount that results in a Cmin of the dextromethorphan in the human being, on the eighth day, that is at least about 20 ng/mL and is at least 20 times the Cmin that would have been achieved by administering the same amount of the dextromethorphan without the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion for 8 consecutive days, and wherein the dextromethorphan is present in the body of the human being at the same time as the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion. 2. The method of claim 1, wherein at least about 40 mg of the dextromethorphan is administered twice a day. 3. The method of claim 1, wherein about 50 mg to about 140 mg of the bupropion is administered twice a day. 4. The method of claim 1, wherein about 45 mg of the dextromethorphan is administered twice a day. 5. The method of claim 1, wherein about 105 mg of the bupropion is administered twice a day. 6. The method of claim 2, wherein about 105 mg of the bupropion is administered twice a day. 7. The method of claim 1, wherein the bupropion is a single enantiomer or is deuterium modified. 8. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 400 ng·hr/mL to 1200 ng·hr/mL. 9. The method of claim 8, wherein about 40 mg to about 200 mg of the bupropion is administered twice a day. 10. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 450 ng·hr/mL to 600 ng·hr/mL. 11. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 500 ng·hr/mL to 600 ng·hr/mL. 12. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 500 ng·hr/mL to 550 ng·hr/mL. 13. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 550 ng·hr/mL to 600 ng·hr/mL. 14. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 650 ng·hr/mL to 1700 ng·hr/mL. 15. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 750 ng·hr/mL to 1000 ng·hr/mL. 16. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 700 ng·hr/mL to 900 ng·hr/mL. 17. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 750 ng·hr/mL to 800 ng·hr/mL. 18. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 800 ng·hr/mL to 850 ng·hr/mL. 19. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 850 ng·hr/mL to 900 ng·hr/mL. 20. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 900 ng·hr/mL to 1000 ng·hr/mL. 21. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1000 ng·hr/mL to 1100 ng·hr/mL. 22. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1100 ng·hr/mL to 1200 ng·hr/mL. 23. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1200 ng·hr/mL to 1300 ng·hr/mL. 24. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1300 ng·hr/mL to 1400 ng·hr/mL. 25. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1400 ng·hr/mL to 1500 ng·hr/mL. 26. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1500 ng·hr/mL to 1600 ng·hr/mL. 27. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1600 ng·hr/mL to 1700 ng·hr/mL. 28. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1700 ng·hr/mL to 1800 ng·hr/mL. 29. The method of claim 1, wherein the dextromethorphan AUC0-12, on the eighth day that the combination is administered, is 1800 ng·hr/mL to 2000 ng·hr/mL.